Li Shuai – CEO, SIMR, China
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Address: Institute of Medicinal Plant Development
151 Ma Lian Wa North Road, Haidian District
Beijing, P.R.China, 100193,China
Tel: +86 10 62899958
Web: www.abo.org.cn
ALLIANCE OF BIO-BOX OUTSOURCING, CHINA (ABO) is a member-based organization, devoted to excellence in providing high quality, efficient and cost-effective services and promoting international collaborations between China and the world.
ABO was founded in 2005 by the Beijing Pharma and Biotech Center (BPBC), together with 10 leading biotech outsourcing providers in China.
ABO provides a broad range of services, from drug discovery, pre-clinical studies, clinical trials, to registration and contract manufacturing. Alliance of Bio-Box Outsourcing China offers hassle-free outsourcing experiences with global quality standards.
Genomics Studies & Proteomics Studies, Genetic Engineering & Protein Engineering, Genetic Therapeutics, Antibody Engineering, Drug Screening Pharmacokinetics & Drug Safety Evaluation, Pilot Plan Trials, Clinical Trials, Contract Manufacturing
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to…
The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial…
Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over…
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
See our Cookie Privacy Policy Here
